Dr. Giselle Saulnier Sholler, director of pediatric oncology research at Penn State College of Medicine and division chief of pediatric hematology and oncology at Penn State Health Golisano Children’s Hospital, sat down with Penn State News to discuss her approach to individualized treatment plans, groundbreaking research findings and her recent move to Penn State Health. In December 2023, the FDA approved eflornithine (DFMO) based on 20 years of research led by Dr. Sholler. DFMO is the first drug to increase survival rates for high-risk pediatric neuroblastoma patients and reduce the risk of relapse. Dr. Sholler is excited to have a larger impact on patients at Penn State Health Children's Hospital working with Four Diamonds funded research that is ready to move forward to clinical trials.
Childhood Cancer
Awareness Month
Is Here
See how our community is making an impact for kids battling cancer and how you can join the fight to conquer childhood cancer.
